Are R&D Intensive Firms Willing to Share Potentially Proprietary Information?
R&D intensive companies, such as pharmaceutical companies, operate in highly competitive environments and, therefore, you would expect that managers of these types of companies would disclose very little information about their operations. This could potentially harm investors and creditors ability to value these types of companies. In fact, one factor contributing to the "stock market bubble" is investors overestimating the future profitability of high technology firms. In addition, research has shown that analysts and other market participants often have difficulty predicting how R&D activities will benefit a company in the future.
Read the rest of this research summary (PDF)
Denise Jones' Faculty Profile 